共查询到19条相似文献,搜索用时 234 毫秒
1.
测定血清CA125水平在卵巢癌的临床意义 总被引:2,自引:0,他引:2
目的分析卵巢癌手术前后测定血清CA125水平的临床意义.方法采用回顾性分析方法,1994年1月~2000年8月我院收治的137例卵巢癌患者手术前后血清CA125水平结合病理、分期、分化、手术情况\治疗及预后等临床资料进行分析.结果在卵巢癌,术前血清CA125水平与病理类型及分期相关(P=0.006),术后2~4个月血清CA125水平与手术的癌细胞减灭程度相关(P=0.025),术后5~7个月血清CA125水平与是否坚持化疗相关(P=0.014),且为预测复发及生存时间的重要因素.术后血清CA125水平的升高可预测复发,其敏感性为87.5%,且通常较临床证实复发提前,平均为7.2个月.结论卵巢癌患者术前测定血清CA125水平可初步反映病理类型及分期,术后监测血清CA125水平可反映手术的肿瘤减灭程度,及时预测复发,并可判断预后. 相似文献
2.
卵巢癌患者血清中TPS、CA125水平及其临床意义 总被引:2,自引:0,他引:2
目的 探讨卵巢癌患者血清TPS、CA125水平的临床应用价值。方法 分别检测15例卵巢良性肿瘤患者(良性对照组)和39例卵巢癌患者(卵巢癌组)初诊、治疗后以及15例卵巢癌复发患者血清TPS、CA125水平,统计结果进行比较。结果卵巢癌组血清TPS、CA125水平显著高于良性对照组(P〈0.01);TPS对卵巢癌诊断的灵敏度和特异度为71.8%和86,7%,CA125为84.6%和86.7%,两者差异无显著性(P〉0.05);治疗后患者血清TPS、CA125水平低于治疗前(P〈0.01、P〈0.05),而复发时TPS水平又显著高于治疗后(P〈0.05)。结论 血清TPS检测有助于卵巢癌诊断、疗效观察及预后判断,联合检测CA125可提高其临床应用价值。 相似文献
3.
目的 分析卵巢上皮性癌(卵巢癌)患者在初次治疗的不同阶段血清CA125水平与卵巢癌复发和预后的关系.方法 收集2002年1月-2005年12月间浙江大学医学院附属妇产科医院经病理检查证实的151例原发性卵巢癌患者的临床病理资料并进行随访,分析初次治疗的不同阶段血清CA125水平与临床病理参数、2年复发率和5年复发率、5年生存率及无瘤生存期和总生存期的相关性.结果 卵巢癌患者术前血清CA125水平、化疗3个疗程结束时CA125是否降为正常与大多数预后相关的临床病理参数相关,包括分期、病理分级、腹水量、残留病灶大小、复发类型、2年复发率、5年复发率及5年生存率(P均<0.05).术前及化疗3个疗程结束时血清CA125水平与无瘤生存期和总生存期呈显著性相关(P均<0.01).但未见手术前后CA125下降幅度与复发和预后的相关性(P均>0.05).结论 术前及化疗3个疗程结束时血清CA125水平可用于预测卵巢癌的复发和预后. 相似文献
4.
目的探讨血清肿瘤标志物CA19-9、CA125及CP2在卵巢黏液性肿瘤诊断和监测中的价值。方法对北京大学人民医院1999年1月至2007年6月间收治的273例卵巢肿瘤患者的临床资料进行回顾性分析,探讨血清肿瘤标志物CA19-9、CA125及CP2在50例卵巢黏液性肿瘤诊断和监测中的价值,并与223例卵巢非黏液性肿瘤进行比较。结果(1)卵巢黏液性肿瘤中,CA19-9的曲线下面积最大(为0.95),其次是CA125(为0.90);而卵巢非黏液肿瘤中,CA125和CP2的曲线下面积最大(均为0.90)。(2)卵巢黏液性肿瘤患者联合检测CA19-9和CA125时,其敏感度(93.8%)较单项检测(CA19-9和CA125分别为75.0%和66.7%)明显提高(P〈0.05),而特异度(分别为86.1%、86.6%和90.2%)无明显变化(P〉0.05)。卵巢非黏液性肿瘤患者联合检测CA125和CP2时的敏感度(85.0%),较CP2(70.6%)单项检测明显提高,差异有统计学意义(P〈0.05);较CA125(80.7%)单项检测虽有提高,但差异无统计学意义(P〉0.05);3者的特异度(分别为90.2%、88.5%和93.9%)比较,差异无统计学意义(P〉0.05)。(3)82例卵巢恶性肿瘤术前血清肿瘤标志物阳性患者中。可行满意的肿瘤细胞减灭术患者[70%(57/82)]的血清肿瘤标志物于术后2个月内降为正常的百分率高于未能行满意肿瘤细胞减灭术者(分别为75%和28%),差异有统计学意义(P〈0.05);且其术后血清肿瘤标志物再次上升的平均时间延长(分别为18.2和16.4个月),但差异无统计学意义(P〉0.05);复发率(分别为35%和56%)及死亡率(分别为14%和32%)降低,差异有统计学意义(P〈0.05)。20例术前血清肿瘤标志物阴性患者均可行满意的肿瘤细胞减灭术,其中复发患者仅2例(10%)。(4)卵巢黏液性肿瘤患者术后复发时多为血清CA19-9水平上升,而卵巢非黏液性肿瘤术后复发时主要为血清CA125水平上升,部分患者血清CP2水平也上升。(5)术前血清肿瘤标志物阳性患者较阴性患者生存率明显下降,其中CA125(+)与CA125(-)、CP2(+)与CP2(-)患者间生存率比较,差异有统计学意义(P〈0.05);而CA19-9(+)与CA19-9(-)患者间生存率比较,差异则无统计学意义(P〉0.05)。结论CA19-9是诊断卵巢黏液性肿瘤的敏感指标,与CA125联合检测可提高对卵巢黏液性肿瘤诊断的敏感度,并对术后监测有重要临床意义。CA125和CP2联合检测则对诊断卵巢非黏液肿瘤更敏感。 相似文献
5.
子宫内膜癌患者血清CP2、CA125、唾液酸和癌胚抗原检测的临床意义 总被引:1,自引:0,他引:1
目的探讨肿瘤标志物CP2、CA125、唾液酸(SA)和癌胚抗原(CEA)检测对子宫内膜癌患者的临床意义。方法选取154例具有肿瘤标志物检测结果的子宫内膜癌患者的临床病理资料进行回顾性分析。结果子宫内膜癌患者血清CP2、SA、CA125和CEA水平升高的百分率分别为23.4%、36.8%、19.0%和30.3%。血清CP2水平升高与手术病理分期、病理分化程度、附件受累、腹腔细胞学检查阳性及盆腔淋巴结转移相关(P值分别为0.002、0.040、0.019、0.019、0.005);血清SA水平升高与附件受累、腹腔细胞学检查阳性相关(P值分别为0.021、0.000);血清CA125水平升高与病理分化程度、宫颈受累和盆腔淋巴结转移相关(P值分别为0.014、0.006、0.018);CEA与各临床病理特征间均无相关性(P均〉0.05)。血清CP2、CA125和CEA水平升高与患者预后相关(P值分别为0.016、0.000、0.016),其中CA125水平与预后关系最为密切。结论子宫内膜癌缺乏特异性肿瘤标志物,CP2与子宫内膜癌临床病理特征相关性较强,CP2、CA125和CEA对患者预后有提示作用。 相似文献
6.
雌激素受体相关受体亚型在卵巢癌中的表达及其与预后的关系 总被引:3,自引:0,他引:3
目的探讨雌激素受体相关受体(ERRs)亚型α、β、γ在卵巢癌中的表达及其与预后的关系。方法激光共聚焦显微镜观察ERRα蛋白在卵巢癌细胞株SKOV3和OVCAR3细胞内的定位。RT-PCR技术检测33份卵巢癌组织以及12份正常卵巢组织中3种ERRs亚型的mRNA表达,并结合临床病理指标分析其预后情况。结果ERRα蛋白主要分布于SKOV3和OVCAR3细胞的细胞核内。卵巢癌组织中ERRα mRNA的阳性表达率(58%)和ERRγ mRNA的阳性表达率(48%)显著高于正常卵巢组织(分别为17%和33%,P〈0.05);ERRβ mRNA的阳性表达率在卵巢癌组织和正常卵巢组织中都很低(分别为9%和0),两者比较,差异无统计学意义(P=0.795)。ERRα mRNA的阳性表达与卵巢癌的手术病理分期(r=0.639,P=0.017)、病理分级(r=0.520,P=0.022)呈正相关。ERRα mRNA阳性表达的卵巢癌患者,其中位数整体生存时间(19.0个月)明显短于ERRα mRNA阴性表达患者(31.5个月,P=0.015),但两者间的无瘤生存时间(分别为12.6和14.5个月)比较,差异无统计学意义(P=0.820);ERRγ mRNA阳性表达患者的中位数无瘤生存时间(18.0个月)显著长于ERRγ mRNA阴性表达患者(13.5个月,P=0.020),但两者间中位数整体生存时间(分别为23.4和19.6个月)比较,差异无统计学意义(P=0.093)。结论ERRα蛋白主要表达于卵巢癌细胞核内。ERRα mRNA高表达与卵巢癌患者的预后差有关,而ERRγ mRNA高表达可能提示患者预后较好。 相似文献
7.
目的 探讨术前血清CA125、VEGF-C、FSH水平对子宫肌瘤患者术后复发的预测价值分析。方法 选取内蒙古自治区人民医院2017年1月至2019年3月收治的126例子宫肌瘤患者,所有患者均行子宫肌瘤剔除术。术后随访3年,评估患者复发情况。比较复发者和未复发者术前血清CA125、VEGF-C、FSH水平,分析术前血清CA125、VEGF-C、FSH水平与子宫肌瘤术后复发的关系及对子宫肌瘤复发的诊断价值。结果 术后随访3年,32例患者复发,复发率25.40%(32/126);与未复发组对比,复发组年龄更小、肌瘤个数更多、合并症比例更高(P <0.05),手术方式、肌瘤大小、手术时间、术中出血量及初潮年龄对比差异均无统计学意义(P>0.05);复发组术前血清CA125、VEGF-C、FSH水平高于未复发组(P <0.05);患者年龄、具有合并症、CA125、VEGF-C、FSH水平是影响子宫肌瘤患者复发的相关因素(P <0.05);术前血清CA125、VEGF-C、FSH及联合检测诊断子宫肌瘤复发的AUC分别为0.791、0.864、0.665、0.937。结论 子... 相似文献
8.
目的:探讨血清C反应蛋白(C-reactive protein,CRP)与上皮性卵巢癌(epithelial ovarian cancer,EOC)临床病理参数、CA125的相关性及评估EOC预后的价值。方法:测定61例EOC患者术前血清CRP及CA125,分析CRP与临床病理参数及CA125的相关性。结果:术前EOC患者血清CRP的中位数为13.06mg/L,CRP阳性者38例(38/61),明显高于对照组(P<0.001)。术前血清CRP水平与EOC的FIGO分期、淋巴结转移、腹水形成关系密切。FIGOⅢ~Ⅳ期、淋巴结转移阳性、腹水形成者CRP中位数显著增高。多因素Logistic回归分析也提示肿瘤FIGO分期、腹水形成和淋巴结转移与CRP阳性表达相关(P<0.05)。研究还表明,CRP水平与手术方式满意度及残余灶大小关系非常密切,CRP值越高,预示手术满意度越差、残余灶越大;血清CRP、CA125的秩和相关分析显示CRP与CA125之间存在正相关(P=0.000)。结论:术前血清CRP可作为判断EOC预后的有价值指标。 相似文献
9.
目的探讨宫颈癌患者的血清血管内皮生长因子(VEGF)水平与宫颈癌临床病理特征及预后的关系。方法采用酶联免疫吸附法(ELISA)检测100例宫颈癌、50例宫颈上皮内瘤变患者和30例正常健康妇女血清中VEGF水平,并进行对照分析。结果宫颈癌患者的血清VEGF水平明显高于宫颈上皮内瘤变患者和健康妇女(P〈0.001),血清VEGF水平与患者的临床分期、分化程度、淋巴结转移、肿瘤大小及浸润深度显著相关(P〈0.001),而与病理类型无明显的相关(P〉0.05),术后血清VEGF平均含量较术前明显下降,术后复发血清VEGF含量较复发前明显升高,差异有显著性(P〈0.001)。结论检测血清VEGF对判断宫颈癌患者的肿瘤负荷、疗效、复发转移、预后都有重要的参考价值。 相似文献
10.
目的 探究血清糖类抗原199(CA199)、糖类抗原125(CA125)、人附睾蛋白4(HE4)水平表达与卵巢癌的相关性。方法 选取60例卵巢癌患者纳入研究组;另选取同期健康体检者60例纳入对照组。两组均采用全自动化学发光免疫分析仪测定血清CA199、CA125、HE4水平以及卵巢癌不同分期患者的血清水平,并分析血清CA199、CA125、HE4水平与卵巢癌的相关性。结果 研究组血清CA199、CA125、HE4水平高于对照组(P<0.05)。研究组卵巢癌Ⅲ~Ⅳ期患者的血清CA199、CA125、HE4水平高于Ⅰ~Ⅱ期患者(P<0.05)。血清CA199、CA125、HE4水平与卵巢癌成正相关(r=0.387、0.379、0.383,P<0.05)。结论 血清CA199、CA125、HE4水平高表达与卵巢癌发病及进展有关,可作为临床预测、诊断、评估病情的关键指标。 相似文献
11.
Yoshikawa T Takano M Kita T Kudoh K Sasaki N Kato M Watanabe A Miyamoto M Goto T Furuya K 《European journal of gynaecological oncology》2012,33(3):269-273
The normal serum CA125 half-life and distribution of the normal serum nadir CA125 value in patients with epithelial ovarian carcinoma (EOC) have not been determined yet. Among patients with EOC, 41 patients met the inclusion criteria of the present study: the patients that underwent complete cytoreductive surgery and six cycles of platinum-containing chemotherapy, and who had no recurrent disease more than five years. Serum CA125 half-life (T1/2) during primary surgery and primary chemotherapy was calculated and serum nadir CA125 level was evaluated by logarithmic-transformed serum CA125. Median value of nadir CA125 was 7 U/ml (range 3-20 U/ml), and the mean ln (serum nadir CA125) was 1.96 +/- 0.45. Mean T1/2 was 10.4 days in all patients, and T1/2 value was associated with the preoperative serum levels of CA125. Predicted slope of CA125 regression curve was also influenced by the preoperative CA125 value. The present study provides fundamental information with regard to normal half-life time and normal nadir of CA125 in EOC patients. 相似文献
12.
卵巢恶性肿瘤患者测定血清血管内皮生长因子的临床价值 总被引:4,自引:1,他引:3
目的 探讨血清血管内皮生长因子 (VEGF)测定对卵巢恶性肿瘤诊断、病程监测和预后的价值。方法 采用酶联免疫吸附法 (ELISA)对 90例健康妇女 (对照组 )、2 5例卵巢良性肿瘤 (良性组 )及 12 0例卵巢恶性肿瘤 (恶性组 )进行血清VEGF含量分析 ,并进一步对其中 2 5例卵巢恶性肿瘤患者进行手术治疗前后血清VEGF含量的动态观察。结果 ( 1)恶性组术前血清VEGF含量为 ( 766±12 3 7)mg/L ,显著高于良性组的 ( 5 6± 2 3 )mg/L及对照组的 ( 5 5± 19)mg/L(P =0 0 0 6) ,以 10 0mg/L为界值 ,其诊断的特异性为 87% ,敏感性为 77% ;( 2 )恶性组临床分期Ⅰ~Ⅱ期和高~中分化患者术前血清VEGF含量分别为 ( 198± 2 87)mg/L和 ( 2 80± 5 5 2 )mg/L ,明显低于临床分期Ⅲ~Ⅳ期的 ( 95 5±1716)mg/L和低分化患者的 ( 991± 13 49)mg/L (P <0 0 5 ) ;但血清VEGF含量与组织学类型无关 (P>0 0 5 ) ;( 3 )手术治疗后血清VEGF含量为 ( 118± 110 )mg/L ,较手术治疗前血清VEGF含量 [( 10 74±12 11)mg/L]明显下降 ;( 4)初治患者血清VEGF阳性者 (即VEGF≥ 10 0mg/L)平均总生存期为 2 8个月 ,而血清VEGF阴性者平均总生存期为 3 5个月 (P <0 0 5 )。但COX模型分析结果发现 ,VEGF不是与卵巢恶性肿瘤预后相关的独立因素 (P 相似文献
13.
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. 总被引:5,自引:0,他引:5
A P Makar G B Kristensen J Kaern O P B?rmer V M Abeler C G Tropé 《Obstetrics and gynecology》1992,79(6):1002-1010
The prognostic significance of the serum CA 125 level was studied in 687 patients with invasive epithelial ovarian malignancies. The samples were collected preoperatively in 200 and postoperatively in 487 patients. Median follow-up was 27 months (range 3-84). The serum CA 125 level was elevated preoperatively in 90% of cases, with a median value of 429 U/mL. In patients with evidence of disease at the time of sampling, the CA 125 serum level correlated directly to tumor stage, tumor load, and histologic grade. Using Cox multivariate analysis, the preoperative serum CA 125 level had no independent prognostic significance, whereas the postoperative level did. In patients without residual disease after primary surgery, histologic type (P less than .0001), postoperative CA 125 level with 35 U/mL as the cutoff value (P = .0009), and tumor grade (P = .034) were independent prognostic factors for survival. For those with residual tumor after primary surgery, histologic type (P less than .0001), postoperative treatment (P = .0002), size of residual disease (P = .0005), and postoperative serum CA 125 level with 65 U/mL as a cutoff (P = .003) were independent prognostic factors. 相似文献
14.
RETRACTED: A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer 总被引:2,自引:0,他引:2
Mitra Modares Gilani Mojgan Karimi Zarchi Fatemeh Ghaemmaghami Nadereh Behtash Azam Sadat Mousavi Soheila Ansaripoor 《Gynecologic oncology》2007,105(3):237-783
OBJECTIVE: To determine the ability of a preoperative serum CA125 to predict optimal primary tumor cytoreduction in patients with stage III and IV epithelial ovarian cancer (EOC). MATERIALS AND METHODS: The records of patients with advanced stage who underwent primary surgery for EOC at Tehran University, Vali-Asr Hospital between 2000 and 2002 were reviewed. Inclusion criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. Without optimal cytoreduction was determined using the receiver operator curve (ROC). RESULTS: One hundred and twenty cases of advanced stage EOC were identified, of which 90 cases of stage III/IV met our inclusion criteria. Serum CA125 < or = 400 was identified with OD > or = 75% of the time. Conversely, optimal cytoreduction was performed in < or = 40% of patients with CA125 > or =4000. The area under the ROC curve for CA125 was 0.680. The optimal cytoreduction rate for those with and without ascites was 38% and 77%, respectively (P<0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.696. CONCLUSION: We conclude that CA125 level did not reliably predict optimal cytoreduction in patients with stage III-IV EOC. 相似文献
15.
16.
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer 总被引:2,自引:0,他引:2
Hefler LA Zeillinger R Grimm C Sood AK Cheng WF Gadducci A Tempfer CB Reinthaller A 《Gynecologic oncology》2006,103(2):512-517
OBJECTIVE: Serum vascular endothelial growth factor (VEGF) levels have been shown to be associated with an adverse outcome in patients with ovarian cancer. We studied the clinical value of serum VEGF as an independent prognostic parameter. METHODS: In the present study, we ascertained preoperative serum VEGF in a series of 314 patients with ovarian cancer: 45 new cases and 269 from four previously published studies. Serum VEGF was evaluated prior to primary surgery, results were correlated with clinical data. RESULTS: Median serum VEGF was 407 (238-746) pg/mL. In a univariate Kaplan-Meier analysis, FIGO stage, residual tumor mass, tumor grade, patients' age, serum CA 125, and preoperative serum VEGF were associated with overall survival. In a multivariate Cox regression model, higher FIGO stage, presence of residual tumor mass after primary surgery, and higher serum VEGF were independently associated with a shortened overall survival. Planned subgroup analysis was performed for patients with ovarian cancer FIGO stage I. In a multivariate Cox regression model, higher tumor grade and higher serum VEGF were the only independent prognosticators for overall survival. Patients with FIGO stage I ovarian cancer and a serum VEGF > or = 380 pg/mL had an 8-fold increased risk for experiencing cancer-related death. CONCLUSION: Serum VEGF is an independent prognostic parameter in patients with all stages of ovarian cancer. 相似文献
17.
B. Pinar Cilesiz Goksedef Husnu Gorgen Safak Yilmaz Baran Murat Api Ahmet Cetin 《Journal d'obstetrique et gynecologie du Canada》2011,33(8):844-850
ObjectiveWe wished to determine the relationship between preoperative serum CA 125 levels and the risk of metastatic disease, recurrent disease, and death in women with endometrial cancer.MethodsWe reviewed the records of women with endometrial adenocarcinoma of all stages who underwent primary surgery. We abstracted multiple data variables, including demographic characteristics, serum CA 125 levels, postoperative histopathology results, progression-free survival, and overall survival rates.ResultsThe records of 97 women with endometrial carcinoma were analyzed. With a serum CA 125 cut-off level of 35 kU/L, the likelihood of disease-related death could be predicted with 70% sensitivity and 83% specificity; disease progression could be predicted with 60% sensitivity and 84% specificity; and lymph node metastasis could be predicted with 75% sensitivity and 84% specificity. There was a significant relationship between a serum CA 125 level ≥ 35 kU/L and depth of myometrial invasion, cervical stromal invasion, stage, frequency of recurrence, and disease-related death. Having deep myometrial invasion, cervical stromal involvement, positive peritoneal cytology, lymph node metastasis, disease recurrence, and disease-related death were each associated with significantly higher mean CA 125 levels. In women with serum CA 125 levels < 35 kU/L, fiveyear progression-free survival rates (88%) and overall survival rates (92%) were significantly better than in women with levels ≥ 35 kU/L (57% and 70%, respectively; P = 0.001 for both).ConclusionSerum CA 125 levels and extension of disease are highly correlated in women with endometrioid endometrial cancer, and elevated CA 125 levels predict a higher risk of disease recurrence and death. 相似文献
18.
PURPOSE OF INVESTIGATION: The aim of our study was to assess whether serum levels of serum insulin-like growth factor-I (IGF-I) could be used for the follow-up of the patients with epithelial ovarian cancer and to identify whether it was superior to serum CA 125. METHODS: Our study group consisted of 28 patients diagnosed with epithelial ovarian cancer who had initial high serum CA 125 levels and have received chemotherapy following the operation. Preoperatively and before each chemotherapy administration, serum CA 125 and IGF-I levels were measured. RESULTS: The mean value of preoperative serum CA 125 was 364.0 +/- 152.9 U/ml. Serum CA 125 levels decreased with chemotherapy (Spearman rs= - 0.641, p=0.000). The mean preoperative serum IGF-I concentration was 58.04 +/- 52.7 ng/ml, and it showed a slight increase with chemotherapy. (Spearman rs=0.3 18, p=0.001). We observed that there was a weak-moderate negative correlation between the two markers, and when chemotherapy was administered serum CA 125 levels which were initially high started to decrease while serum IGF-I levels showed a mild increase (Spearman rs= - 0.350, p=0.000). CONCLUSION: The measurement of serum IGF-I does not provide any additional benefit in monitoring the response of the disease to chemotherapy. 相似文献
19.
Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma 总被引:1,自引:0,他引:1
B. GRONLUND H. DEHN† C.K. HØGdall†‡ S.A. ENGELHOLM M. JØRGENSEN B. NØRGAARD-PEDERSEN‡ & E.V.S. HØGDALL‡§ 《International journal of gynecological cancer》2005,15(5):836-843
The aim was to examine the value of the pretherapeutic serum cancer-associated serum antigen (CASA) level as a prognostic factor for survival in patients with recurrent epithelial ovarian carcinoma. Serum levels of CASA and cancer antigen (CA)125 were prospectively determined in 70 consecutive patients with recurrent ovarian cancer before the start of second-line chemotherapy. Univariate and multivariate analyses of survival were performed. The median level of serum CASA was 6.5 U/mL (range: 0.2-1437 U/mL). Univariate analysis showed that patients with a CASA level >10.0 U/mL had significantly shorter survival than patients with CASA level < or =10.0 U/mL (P= 0.002). Using different CASA cutoff levels (6.0, 6.5, and 10.0 U/mL), multivariate Cox analyses identified CASA as an independent prognostic factor for survival at every cutoff level. The strongest prognostic function for CASA was found at a cutoff level of 10.0 U/mL (>10 vs < or =10 U/mL; hazard ratio, 2.7; 95% confidence interval, 1.6-4.7; P < 0.001). The pretreatment CA125 level was not found to be significantly associated with survival by any of the cutoffs (35, 65, 132, and 339 U/mL). A pretreatment elevated level of the tumor marker CASA is an adverse prognostic factor for survival in patients with ovarian cancer relapse. 相似文献